Drug Target Review

NOVEMBER 8, 2023

Cell therapies hold immense promise for revolutionising the treatment of some of the most challenging diseases, but several technological and logistical hurdles stand in the way of unlocking their full potential. These patients typically fail frontline chemotherapies within 8 months of treatment and have few options for second line therapies.

Therapies 116

Therapies Engineering Treatment Molecular Biology 116

Drug Target Review

AUGUST 29, 2024

However, these treatments will eventually fail for the majority of patients, so there is a strong need for better CAR therapies. How might the CD5 knockout approach impact the treatment of other types of cancers beyond T-cell lymphoma?

Therapies 59

Therapies Treatment Engineering Molecular Biology 59

Drug Target Review

JULY 1, 2024

As a non-opioid, SRP-001 also eliminates abuse potential, positioning it as a safer and effective drug candidate for the treatment of acute and neuropathic pain and migraine headache. How does SRP-001’s safety profile, especially concerning hepatotoxicity and nephrotoxicity, compare to other common pain medications?

Treatment 59

Treatment Clinical Trials Therapies Molecular Biology 59

Drug Target Review

FEBRUARY 26, 2024

Rather than solely identifying tumour-associated mutations which can be specifically targeted for effective treatment, we now need to consider how non-mutational events play into both the development of the primary tumour and the development of therapy resistance. Dr Alani received her M.D.

Therapies 59

Therapies Molecular Biology Medical Schools Regulations 59

Broad Institute

JUNE 21, 2023

Now, researchers at the Broad Institute of MIT and Harvard have found that treatment with continuous hypoxia — low-oxygen conditions comparable to levels at a Mount Everest base camp — restores balance and coordination in a mouse model of Friedreich’s ataxia. A few treatments stood out.

Treatment 98

Treatment Disease Molecular Biology Medical Schools 98

Broad Institute

AUGUST 7, 2023

Now, a team of MIT, Massachusetts General Hospital (MGH), Broad Institute of MIT and Harvard, and Harvard Medical School (HMS) researchers has discovered how STING activates those two pathways. Food and Drug Administration has not approved any STING agonist thus far, although multiple clinical trials are currently underway.

Regulations 91

Regulations Clinical Trials Engineering Science 91

Broad Institute

JANUARY 30, 2024

In others, an infection can cause the immune system to spin out of control, leading to sepsis — organ dysfunction that lacks effective treatments and is often fatal. In 2005, Bhattacharyya completed PhD studies at the University of California, San Francisco, in biochemistry and molecular biology, followed by two years of medical training.

Hospitals 137

Hospitals Medical Schools Virus Science 137